Ryan Sysko and the second life of a first pitch

Ryan Sysko brought the old slides. In November 2013, at an Entrepreneur Expo in Maryland, the Welldoc co-founder recreated an early fundraising pitch using the presentation he had taken to investors in 2005. Across from him was Randy Domolky, managing director of TEDCO Capital Partners. The company in those slides had a prototype, an unfinished business model and plenty still to figure out.

Domolky played along. He declined the pretend investment and joked that Sysko should call him in a few years. The audience got a demonstration of the distance between a promising idea and a business someone will finance. A pitch deck can grow old without becoming less instructive. Sometimes the embarrassing version is the one worth keeping.

By the time he staged that replay, Sysko said Welldoc had raised roughly $30 million from local angel investors and employed 90 people in Baltimore and Bangalore. The early slides had survived long enough to become teaching material. The contrast gave the room something a polished success presentation rarely supplies: a view of a company before its founders had answers.

An education in reaching people

Sysko’s working life had already crossed several kinds of business. He held management roles at Chase, Bank of America and Conseco. He founded Assurance Marketing Group in Wilmington, Delaware, and later worked in marketing and business development at The Credo Group. Internet distribution was part of that earlier world. Long before his name appeared beside Welldoc, he was working on how an offer reaches a customer.

It is a useful background for understanding the questions that recur in his career. Building a product leaves a founder with the problem of getting it used. A buyer must understand the offer. A partner must have a reason to participate. A business model must survive contact with the person being asked to pay. Those are commercial questions, and Sysko arrived with commercial experience.

He graduated from Lafayette College in 1997 with a degree in economics and business. Looking back, he credited the breadth of his education and close contact with faculty. His own description was plain: “I don’t think of myself as a specialist.” Then the shorter version: “I really am a generalist.”

“I really am a generalist.”

Ryan Sysko, 2010

The word suits a career that moves between financing, marketing and partnerships. It also leaves room for specialists. A generalist running a company still needs people who can answer questions outside his experience. In Sysko’s case, the relationships become as interesting as the sequence of titles.

One of those relationships began long before any organization chart. Suzanne Clough is his sister. A conversation during a family vacation in Florida in 2004 preceded their founding of Welldoc the following year. A family conversation became a working partnership, then an enterprise with employees, investors and outside agreements. The change in scale is striking; the sibling connection remains a simple human detail beneath it.

A deal that left the door open

In 2010, Welldoc entered a strategic partnership with AT&T. One feature of the arrangement caught Sysko’s attention: the application was intended to remain accessible across devices and mobile networks. He welcomed AT&T’s willingness to support that approach. Someone using another carrier would still be able to use the software.

That detail deserves more space than it usually gets in a founder’s story. Distribution agreements can determine who can enter the room. If adopting a product requires changing the device or network someone already uses, the agreement has introduced another task before the product gets its chance. The AT&T arrangement addressed that obstacle directly.

Seen alongside his earlier internet marketing work, it gives the generalist description a practical meaning. The product and the route to its user were both part of the business. A partnership with a large company could expand the route while preserving access beyond that partner’s own network. It was a specific commercial choice, with consequences for how the software could travel.

The second company, with familiar faces

Sysko went on to found Amalgam Rx in 2016. Clough was a co-founder there too. Welldoc had given them a shared history; Amalgam gave that working relationship another company in which to operate. Sysko’s current role is founder and CEO of Amalgam. His Welldoc roles belong to the earlier chapter.

The continuity extends beyond the siblings. Amalgam’s technical leadership includes Matti Prasad, whose earlier work at Welldoc involved its mobile and web platforms. Chris Bergstrom, another Welldoc alumnus, also joined Amalgam’s leadership. A new company name can sit above people who have already worked through difficult problems together.

Amalgam also added capabilities through acquisitions. In January 2021, it announced the purchase of Avhana. Later that year it acquired the assets of Geetha, a conversational AI company. The two transactions brought different kinds of software expertise into the business. They show a founder building through combinations as well as through internal development.

The Geetha transaction had a personnel chapter: founder Bharath Sudharsan joined Amalgam as chief data scientist and head of AI. The acquisition included technology operating in 40 languages, tools for creating virtual agents and algorithms intended to learn from interactions. The person behind the acquired company became part of the executive team responsible for what came next.

That arrangement makes the generalist’s job easier to picture. Sysko did not need to claim every specialty as his own. The company could bring in technology and give its creator a leadership role. The organizational decision mattered alongside the asset purchase. A transaction announcement is brief; deciding how the people and their work fit together takes longer.

The people beside the signature

Another recurring relationship sits in a less photographed part of company building: legal advice. Sysko has publicly praised Nemphos Braue, the corporate law firm that works with Amalgam. In a testimonial, he said its attorneys “think like entrepreneurs, which is unusual for attorneys.” It is a compliment with a small elbow attached.

His longer comments emphasized practical judgment about risk and reward. That is a revealing subject for a founder to choose when discussing lawyers. Agreements record obligations, allocate rights and set the terms on which companies work together. The advice around them affects what a business can attempt and what it must accept in return.

In a 2024 business case study, Sysko appeared alongside Jenni Main, then Amalgam’s COO and CFO, to discuss the relationship with George Nemphos and Lauren Ziegler. Main described a closeness comparable to having in-house counsel. The conversation placed legal work inside the operating story, beside finance and executive decisions.

Amalgam’s partnership with Novo Nordisk supplies another example of a relationship developing over time. A collaboration launched in Brazil in 2019. In December 2022, the companies announced an expanded global agreement, and Novo Nordisk made an equity investment in Amalgam. The commercial relationship and the investment relationship were now connected.

That sequence matters. The later announcement followed years of working together. It gives the partnership a history beyond the day a new agreement was signed. For Sysko, it is another chapter in the work of getting a company’s capabilities into a larger organization’s plans.

Read the word after the number

The financing history changes as the companies change. Welldoc’s early backing included local angels. In 2014, a $20 million round brought in Merck’s investment fund and Windham Venture Partners. At Amalgam, CVS Health Ventures participated in the Series B announced in October 2023. These were distinct transactions, involving different businesses and stages.

Then came Catalio Capital Management’s $20 million credit investment in August 2025. The number was easy to recognize. The structure deserved equal attention: a senior secured term loan, with an initial $12 million draw at closing. The stated uses included expansion and refinancing existing corporate debt.

Those details prevent a misleadingly tidy story. Angel backing, strategic equity and secured borrowing serve different purposes and come with different arrangements. Adding their headline numbers together would conceal the decisions that make each one interesting. Sysko’s career is easier to understand when the distinctions stay visible.

The Catalio agreement also connected Amalgam to an investor network and added Nicholas von Guionneau as a board observer. Nemphos Braue represented Amalgam in the transaction. Several threads of the story meet in that announcement: financing, relationships, outside expertise and plans for the next phase of the company.

A newer model, an older question

In June 2026, Amalgam’s Chiron received the AI Breakthrough Award for Overall Large Language Model of the Year. The recognition followed its 2024 award for Best Large Language Model Application. It was a company achievement, involving technical work by a team whose development had included the earlier acquisitions.

An award gives a business a public milestone. Sysko’s longer story runs through the decisions between such dates: finding collaborators, negotiating access, bringing in expertise and arranging capital. His stated plans for Amalgam include further product development and commercial expansion. Each creates another set of practical questions for the founder and his colleagues.

The old pitch deck is a useful place to leave him. In 2013, he put an earlier version of the business back in front of an investor and an audience. The demonstration allowed the uncertainty to remain visible. Eight years of subsequent work had changed the company, but the first slides still had something to say. Keeping them turned out to be a sound editorial decision.